As of 2026-03-31, the Intrinsic Value of Bio Rad Laboratories Inc (BIO) is 165.08 USD. This BIO valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 270.36 USD, the upside of Bio Rad Laboratories Inc is -38.90%.
The range of the Intrinsic Value is 109.77 - 224.91 USD
Based on its market price of 270.36 USD and our intrinsic valuation, Bio Rad Laboratories Inc (BIO) is overvalued by 38.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (60.15) - (42.33) | (46.47) | -117.2% |
| DCF (Growth 10y) | (20.48) - 20.57 | (11.11) | -104.1% |
| DCF (EBITDA 5y) | 109.77 - 224.91 | 165.08 | -38.9% |
| DCF (EBITDA 10y) | 95.26 - 224.27 | 154.28 | -42.9% |
| Fair Value | 140.77 - 140.77 | 140.77 | -47.93% |
| P/E | 626.73 - 794.04 | 688.47 | 154.7% |
| EV/EBITDA | 104.07 - 228.65 | 169.69 | -37.2% |
| EPV | 11.28 - 24.00 | 17.64 | -93.5% |
| DDM - Stable | 282.83 - 1,003.52 | 643.18 | 137.9% |
| DDM - Multi | 371.71 - 1,044.70 | 550.70 | 103.7% |
| Market Cap (mil) | 7,297.02 |
| Beta | 0.97 |
| Outstanding shares (mil) | 26.99 |
| Enterprise Value (mil) | 7,970.22 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.75% |
| Cost of Debt | 5.50% |
| WACC | 8.10% |